New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics

References

• Duchenne muscular dystrophy (DMD) | muscular dystrophy association. [Internet]. [cited 2019 Oct 27]. Available from: https://www.mda.org/disease/duchenne-muscular-dystrophy
   Google Scholar
• About duchenne muscular dystrophy | espeRare foundation. [Internet]. [cited 2019 Oct 27]. Available from: https://esperare.org/en/about-duchenne-muscular-dystrophy
   Google Scholar
• Malik V, Rodino-Klapac LR, Viollet L, et al. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord. [Internet]. 2010 [cited 2019 Oct 28];3:379–389. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21179598
   PubMedGoogle Scholar
• Zhong J, Xie Y, Bhandari V, et al. Clinical and genetic characteristics of female dystrophinopathy carriers. Mol Med Rep. 2019;19:3035–3044.
   PubMed Web of Science ®Google Scholar
• Duchenne UK. Girls living with duchenne | duchenne UK. [Internet]. 2019 [cited 2020 Feb 4]. Available from: https://www.duchenneuk.org/girls-living-with-duchenne
   Google Scholar
• Kieny P, Chollet S, Delalande P, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56:443–454.
   PubMedGoogle Scholar
• Patient education: overview of muscular dystrophies (beyond the basics) - uptodate. [Internet]. [cited 2020 Jan 16]. Available from: https://www.uptodate.com/contents/overview-of-muscular-dystrophies-beyond-the-basics#H8
   Google Scholar
• Shimizu-Motohashi Y, Komaki H, Motohashi N, et al. Restoring dystrophin expression in duchenne muscular dystrophy: current status of therapeutic approaches. J Pers Med. 2019;9:1–14.
   PubMed Web of Science ®Google Scholar
• Gloss D, Moxley RT, Ashwal S, et al. Practice guideline update summary: corticosteroid treatment of duchenne muscular dystrophy - report of the guideline development subcommittee of the American academy of neurology. Neurology. 2016;86:465–472.
   PubMed Web of Science ®Google Scholar
• Conklin LS, Damsker JM, Hoffman EP, et al. Phase IIa trial in duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug HHS public access graphical abstract. Pharmacol Res. 2018;136:140–150.
   PubMed Web of Science ®Google Scholar
• Mcdonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. www.thelancet.com [Internet]. 2018 [cited 2019 Oct 22]. 391:451. Available from: http://dx.doi.org/10.1016/
   Google Scholar
• Drugs@FDA: FDA approved drug products. [Internet]. [cited 2019 Oct 22]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009766
   Google Scholar
• Rahman MM, Hannan MA, Mondol BA, et al. Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull. 2001;27:38–42.
   PubMedGoogle Scholar
• Prednisone - Lexicomp. [Internet]. [cited 2019 Oct 22]. Available from: http://online.lexi.com
   Google Scholar
• Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. . Corticosteroids for the treatment of duchenne muscular dystrophy. In: Cochrane database syst. rev. John Wiley and Sons Ltd; 2016. doi: 10.1002/14651858.CD003725.pub4.
   Google Scholar
• Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123–2131.
   PubMed Web of Science ®Google Scholar
• Werneck LC, Lorenzoni PJ, Ducci RD-P, et al. Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr. 2019;77:579–589.
   PubMed Web of Science ®Google Scholar
• Cowen L, Mancini M, Martin A, et al. Variability and trends in corticosteroid use by male United States participants with duchenne muscular dystrophy in the duchenne registry. BMC Neurol. 2019;19.doi: 10.1186/s12883-019-1304-8
   PubMed Web of Science ®Google Scholar
• Shieh PB. emerging strategies in the treatment of duchenne muscular dystrophy. Neurotherapeutics. Internet] 2018 [cited 2019 Oct 8];15:840–848. Available from. ;:… .
   PubMed Web of Science ®Google Scholar
• Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol 18, 1(2017). doi:10.1186/s40360-016-0111-8.
   Google Scholar
• Cushing’s syndrome: learn about symptoms and treatment. [Internet]. [cited 2019 Oct 29]. Available from: https://www.medicinenet.com/cushings_syndrome/article.htm
   Google Scholar
• Enright PL. The six-minute walk test. Respir Care. 48, 8;2003;783–785.
   PubMedGoogle Scholar
• Shieh PB, Mcintosh J, Jin F, et al. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle Nerve. 2018;58:639–645.
   PubMed Web of Science ®Google Scholar
• Deflazacort - Lexicomp. [Internet]. [cited 2019 Oct 22]. Available from: http://online.lexi.com
   Google Scholar
• Emflaza medicare coverage and co-pay details - goodRx. [Internet]. [cited 2019 Oct 29]. Available from: https://www.goodrx.com/emflaza/medicare-coverage
   Google Scholar
• Request for prior authorization deflazacort (Emflaza). [cited 2019 Oct 28]; Available from: http://www.iowamedicaidpdl.com/sites/default/files/ghs-files/prior-authorization-forms/2017-08-23/emflaza-pa-form-npi-oct-2017.pdf
   Google Scholar
• Your 2018 prescription drug list Oxford connecticut four-tier. [Internet]. 2018 [cited 2019 Oct 28]. Available from: https://www.oxhp.com/druglist/CTAdvantage3TierPDL.pdf
   Google Scholar
• Caremark. FEP 5 tier rx drug formulary (607) standard option. [Internet]. [cited 2019 Oct 28]. Available from: https://www.caremark.com/portal/asset/z6500_drug_list.pdf
   Google Scholar
• Finanger E, Vandenborne K, Finkel RS, et al. Phase 1 study of edasalonexent (CAT-1004), an oral NF-κ B inhibitor, in pediatric patients with duchenne muscular dystrophy. J Neuromuscul Dis. 2019;6:43–54.
   PubMedGoogle Scholar
• Donovan JM, Zimmer M, Offman E, et al. A novel NF-κB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J Clin Pharmacol. 2017;57:627–639.
   PubMed Web of Science ®Google Scholar
• Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. Vamorolone trial in duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurol. 2019;93:1312–1323.
   PubMed Web of Science ®Google Scholar
• Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol. 2011;7,13;2011. doi:10.1186/1710-1492-7-13.
   Web of Science ®Google Scholar
• Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104:375–381.
   PubMed Web of Science ®Google Scholar
• Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons in duchenne muscular dystrophy. Ann Neurol. 2010;67:771–780.
   PubMed Web of Science ®Google Scholar
• Aminoglycosides – UpToDate. [Internet]. [cited 2019 Oct 23]. Available from: https://www.uptodate.com/contents/aminoglycosides#H6
   Google Scholar
• Kimura S, Ito K, Miyagi T, et al. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy. Brain Dev. 2005;27:400–405.
   PubMed Web of Science ®Google Scholar
• Politano L, Nigro G, Nigro V, et al. Gentamicin administration in duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003;22:15–21.
   PubMedGoogle Scholar
• Prednisone – MICROMEDEX. [Internet]. [cited 2019 Nov 4]. Available from: https://www-micromedexsolutions-com
   Google Scholar
• Taguchi A, Hamada K, Shiozuka M, et al. Structure-activity relationship study of leucyl-3-epi-deoxynegamycin for potent premature termination codon readthrough. ACS Med Chem Lett. 2017;8:1060–1065.
   PubMed Web of Science ®Google Scholar
• Hamada K, Omura N, Taguchi A, et al. New negamycin-based potent readthrough derivative effective against TGA-type nonsense mutations. 2019 [cited 2019 Oct 28]. Available from: https://pubs.acs.org/sharingguidelines
   Google Scholar
• McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489–1498.
   PubMed Web of Science ®Google Scholar
• PTC therapeutics receives formal dispute resolution request decision from the FDA’s office of new drugs. [Internet]. [cited 2019 Oct 24]. Available from: https://www.drugs.com/nda/translarna_180220.html
   Google Scholar
• Translarna | European medicines agency. [Internet]. [cited 2019 Oct 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/translarna
   Google Scholar
• Long-term outcomes of ataluren in duchenne muscular dystrophy - full text view - clinicalTrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03179631?term=ataluren&cond=Duchenne+Muscular+Dystrophy&draw=3&rank=12
   Google Scholar
• Long-term outcomes of ataluren in duchenne muscular dystrophy - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT03179631
   Google Scholar
• Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. [Internet]. 2020 [cited 2020 Feb 10]; cer-2019-0171. Available from: https://www.futuremedicine.com/doi/10.2217/cer-2019-0171
   PubMed Web of Science ®Google Scholar
• Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91.
   PubMed Web of Science ®Google Scholar
• Waldrop MA, Flanigan KM. Update in duchenne and becker muscular dystrophy. Curr Opin Neurol. 2019;32:722–727.
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for duchenne muscular dystrophy mutations. Hum Mutat. 2009;30:293–299.
   PubMed Web of Science ®Google Scholar
• Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014;13:987–996.
   PubMed Web of Science ®Google Scholar
• A clinical study to assess two doses of GSK2402968 in subjects with duchenne muscular dystrophy (DMD) - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01462292?term=NCT01462292&draw=2&rank=1
   Google Scholar
• Goemans N, Mercuri E, Belousova E, et al. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in duchenne muscular dystrophy. Neuromuscul Disord. 2018;28:4–15.
   PubMed Web of Science ®Google Scholar
• Tsoumpra MK, Fukumoto S, Matsumoto T, et al. Peptide-conjugate antisense based splice-correction for duchenne muscular dystrophy and other neuromuscular diseases. In: Elsevier BV, editor. EBioMedicine. 2019. p. 630–645.
   Google Scholar
• Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F,  Sepodes B, Vroom E, and Balabanov P. Development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. In: Nucleic acid ther. Mary Ann Liebert Inc.; 2017. p. 251–259. doi: 10.1089/nat.2017.0682
   Google Scholar
• Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395–402.
   PubMed Web of Science ®Google Scholar
• Shimizu-Motohashi Y, Murakami T, Kimura E, et al. Exon skipping for duchenne muscular dystrophy: A systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13;93 doi:10.1186/s13023-018-0834-2.
   Web of Science ®Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605.
   PubMed Web of Science ®Google Scholar
• Dystrophy M, Mendell JR, Rodino-klapac LR. Eteplirsen for the treatment of duchenne eteplirsen for the treatment of duchenne muscular dystrophy. 2013. 74(5); p. 637–647.
   Google Scholar
• FDA. Accelerated approval - NDA 206488. [Internet]. 2016 [cited 2019 Oct 28]. Available from: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
   Google Scholar
• Eteplirsen - Lexicomp [Internet]. [cited 2019 Oct 24]. Available from: http://online.lexi.com
   Google Scholar
• Califf RM. Center for drug evaluation and research. 2016 [cited 2019 Oct 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_summaryreview_Redacted.pdf
   Google Scholar
• Kesselheim AS, Avorn J. Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA - J Am Med Assoc Am Med Assoc. 2016;316:2357–2358.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in duchenne muscular dystrophy. Ann Neurol. 2016;79:257–271.
   PubMed Web of Science ®Google Scholar
• Echigoya Y, Lim KRQ, Trieu N, et al. Quantitative antisense screening and optimization for exon 51 skipping in duchenne muscular dystrophy. Mol Ther. 2017;25:2561–2572.
   PubMed Web of Science ®Google Scholar
• Study of SRP-4045 and SRP-4053 in DMD patients - full text view - clinicalTrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02500381
   Google Scholar
• An extension study to evaluate casimersen or golodirsen in patients with duchenne muscular dystrophy - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03532542
   Google Scholar
• FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation | FDA [Internet]. [cited 2020 Feb 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation
   Google Scholar
• Muntoni F, Frank D, Sardone V, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in duchenne muscular dystrophy patients with mutations amenable to exon 53 skipping (S22.001). Neurology. Internet]. 2018;90:S22.001. Available from. ;:. : http://n.neurology.org/content/90/15_Supplement/S22.001.abstract
   Web of Science ®Google Scholar
• Muntoni F, Tejura B, Spinty S, et al. A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric duchenne muscular dystrophy patients on a balanced diet. Clin Pharmacol Drug Dev. 2019;8:922–933.
   PubMed Web of Science ®Google Scholar
• Péladeau C, Adam NJ, Jasmin BJ. Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression. [cited 2019 Oct 8]. Available from: www.fasebj.org
   Google Scholar
• Péladeau C, Ahmed A, Amirouche A, et al. Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles. Hum Mol Genet. 2015;25:24–43.
   PubMed Web of Science ®Google Scholar
• PoC study to assess activity and safety of SMT C1100 (Ezutromid) in boys with DMD - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02858362?term=PhaseOut+DMD&rank=1
   Google Scholar
• Gene transfer clinical trial to deliver rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03333590
   Google Scholar
• Nakamura K, Kamouchi M, Kitazono T, et al. Role of NHE1 in calcium signaling and cell proliferation in human CNS pericytes. Am J Physiol - Hear Circ Physiol. 2008;294(4):H1700–7.
   Web of Science ®Google Scholar
• Rimeporide (EMD 87580) - muscular dystrophy news [Internet]. [cited 2019 Nov 4]. Available from: https://musculardystrophynews.com/rimeporide-emd-87580/
   Google Scholar
• Rimeporide in patients with duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Nov 4]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02710591?term=rimeporide&rank=1
   Google Scholar
• Watanabe N, Nagata T, Satou Y, et al. NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2018;13:442–449.
   PubMedGoogle Scholar
• NS pharma announces NDA accepted for filing by the FDA for antisense oligonucleotide viltolarsen - parent project muscular dystrophy [Internet]. [cited 2020 Feb 10]. Available from: https://www.parentprojectmd.org/ns-pharma-announces-nda-accepted-for-filing-by-the-fda-for-antisense-oligonucleotide-viltolarsen/
   Google Scholar
• Wu RP, Youngblood DS, Hassinger JN, et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res. 2007;35:5182–5191.
   PubMed Web of Science ®Google Scholar
• Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for duchenne muscular dystrophy. Biochim Biophys Acta - Biomembr. 2010;1798:2296–2303.
   PubMed Web of Science ®Google Scholar
• Parent project muscular dystrophy annual conference [Internet]. 2018 [cited 2019 Oct 29]. Available from: https://www.parentprojectmd.org/get-involved/attend-events/annual-conference/2018-presentations/
   Google Scholar
• Wood M, Zhang J, Bowman K, et al. WVE-210201, an investigational stereopure oligonucleotide therapy for duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration. Neuromuscul Disord. 2017;27:S217.
   Web of Science ®Google Scholar
• Safety and tolerability of WVE-210201 in patients with duchenne muscular dystrophy - full text view - clinicalTrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03508947
   Google Scholar
• Efficacy and safety study of WVE-210201 (Suvodirsen) with open-label extension in ambulatory patients with duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03907072?term=WVE-210201&rank=1
   Google Scholar
• Wave life sciences announces discontinuation of suvodirsen development for duchenne muscular dystrophy nasdaq: WVE[Internet]. [cited 2020 Feb 10]. Available from: http://www.globenewswire.com/news-release/2019/12/16/1960830/0/en/Wave-Life-Sciences-Announces-Discontinuation-of-Suvodirsen-Development-for-Duchenne-Muscular-Dystrophy.html
   Google Scholar
• What is CRISPR, and how does it work? [Internet]. [cited 2019 Oct 29]. Available from: https://curiosity.com/topics/what-is-crispr-and-how-does-it-work-curiosity/
   Google Scholar
• Hale CR, Zhao P, Olson S, et al. RNA-guided RNA cleavage by a CRISPR RNA-cas protein complex. Cell. 2009;139:945–956.
   PubMed Web of Science ®Google Scholar
• Wein N, Vulin A, Falzarano MS, et al. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med. 2014;20:992–1000.
   PubMed Web of Science ®Google Scholar
• Systemic gene delivery clinical trial for duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03375164
   Google Scholar
• Microdystrophin gene transfer study in adolescents and children with DMD - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03368742
   Google Scholar
• A study to evaluate the safety and tolerability of PF-06939926 Gene therapy in duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03362502
   Google Scholar
• Sarepta reports positive preliminary findings in DMD gene therapy trial - muscular dystrophy association [Internet]. [cited 2019 Oct 29]. Available from: https://strongly.mda.org/sarepta-reports-positive-preliminary-findings-in-dmd-gene-therapy-trial/
   Google Scholar
• Usas A, Mačiulaitis J, Mačiulaitis R, et al. Skeletal muscle-derived stem cells: implications for cell-mediated therapies. Medicina (Kaunas). Internet]. 2011 [cited 2019 Nov 4];47:469–479. Available from. ;:. . : http://www.ncbi.nlm.nih.gov/pubmed/22156603
   PubMed Web of Science ®Google Scholar
• Sharma A, Sane H, Badhe P, et al. A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients. Cell Transplant. Internet]. 2013 [cited 2020 Feb 10];22:127–138. Available from. ;:. . : http://journals.sagepub.com/doi/full/10.3727/096368913X672136
   PubMed Web of Science ®Google Scholar
• Schnitzler ER, Rao Passi G, Jacobson R, et al. Efficacy and the safety of granulocyte colony-stimulating factor treatment in patients with muscular dystrophy: a non-randomized clinical trial. Randomized Clin Trial Front Neurol. Internet]. 2017 [cited 2019 Oct 8];8:566. Available from: www.frontiersin.org
   PubMed Web of Science ®Google Scholar
• Bhagavati S. Questions about efficacy of exon-skipping therapy for duchenne muscular dystrophy. Ann Neurol. Internet]. 2014 [cited 2019 Nov 7];75:326–329. 10.1002/ana.24085.
   PubMed Web of Science ®Google Scholar
• Committee P and CNSDA. Eteplirsen briefing document [Internet]. 2016 [cited 2019 Nov 7]. Available from: https://www.fda.gov/media/97306/download
   Google Scholar
• Mutation-specific therapies - parent project muscular dystrophy [Internet]. [cited 2019 Nov 4]. Available from: https://www.parentprojectmd.org/about-duchenne/what-is-duchenne/types-of-mutations/mutation-specific-therapies/
   Google Scholar
• Muntoni F, Desguerre I, Guglieri M, et al. Ataluren use in patients with nonsense mutation duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE registry. J Comp Eff Res. 2019;8:1187–1200.
   PubMed Web of Science ®Google Scholar